GlassScriptPhysician profile
Robert Alan Rahe
NPI 1013212604
$11,467.31
in general payments reported to CMS, 2019-2025
67 companies · $3,113 in 2025
The $3,113 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,415 · 2022: $1,935 · 2023: $2,409 · 2024: $2,594 · 2025: $3,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,000 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,999.62 |
| Education | $116.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,813.60 | 2021-2025 | |
| Ucb, INC. | $765.92 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $690.59 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $472.69 | 2022-2025 | |
| Lilly USA, LLC | $449.61 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $440.72 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $396.11 | 2021-2025 | Uplizna, Aimovig |
| Acadia Pharmaceuticals INC | $353.86 | 2021-2025 | Nuplazid, Daybue |
| Amneal Pharmaceuticals LLC | $315.63 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Eisai INC. | $311.52 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $289.41 | 2023-2025 | Rexulti |
| Abbott Laboratories | $282.35 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $277.58 | 2021-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $260.71 | 2021-2025 | Mavenclad |
| Genentech USA, INC. | $260.34 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rahe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.